文献速递神经肿瘤

少突胶质细胞瘤切除术后辅助放化疗与单纯化疗比较:基于监测、流行病学和最终结果(SEER)数据库的分析

Adjuvant Chemoradiation Therapy Versus Chemotherapy Alone for Resected Oligodendroglioma: A Surveillance, Epidemiology and End Results (SEER) Analysis.
PubMed 文献 · World Neurosurg · 2022-10-20

基于SEER数据库的回顾性分析纳入1826例少突胶质细胞瘤切除术后患者,比较辅助化疗(CT,n=503)与辅助放化疗(CRT,n=1323)的生存获益。倾向性匹配后CT组与CRT组各501例,CT组总生存优于CRT组(中位总生存146个月 vs 111个月);亚组分析显示在多数临床特征亚组中CT组总生存改善更显著(P < 0.05)。

要点

  • 倾向性匹配后,CT组中位总生存146个月 vs CRT组111个月,CT组总生存更优。
  • 亚组分析中,CT组总生存改善在年轻或年长、男性或女性、白人、额叶及顶叶肿瘤部位、肿瘤较小(≤4 cm)及全切除(GTR)患者中更显著(P < 0.05)。
  • 多因素分析中,高龄、白人及其他种族、颞叶及顶叶肿瘤部位为总生存的独立危险因素。

核心结论

  • 在少突胶质细胞瘤切除术后患者中,辅助CT与更好的生存相关,优于辅助CRT。
  • 该生存获益在年轻或年长、男性或女性、白人、额叶及顶叶肿瘤部位、肿瘤较小(≤4 cm)及GTR患者中更显著。

研究设计与样本

  • 基于SEER数据库的回顾性分析,纳入接受少突胶质细胞瘤切除术的患者。
  • 共纳入1826例接受辅助治疗的患者,其中辅助CT组503例,辅助CRT组1323例。
  • 采用多因素Cox回归分析评估影响生存率的因素,并采用倾向性匹配分析以减少各组选择偏倚。
  • 按患者临床特征进行亚组分析;1:1倾向性匹配后纳入CT组501例和CRT组501例。

主要发现

  • 多因素分析显示,高龄、白人及其他种族、颞叶及顶叶肿瘤部位为总生存的独立危险因素。
  • 1:1倾向性匹配后,CT组总生存率优于CRT组(中位总生存:146个月 vs 111个月)。
  • 亚组分析显示,CT组总生存改善在年轻或年长、男性或女性、白人、额叶及顶叶肿瘤部位、肿瘤较小(≤4 cm)及GTR患者中更显著(P < 0.05)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: The benefit of postoperative adjuvant therapy for survival of oligodendrocyte glioma remains unclear. In this study, we compared the effect of chemoradiation therapy (CRT) and chemotherapy (CT) alone in patients who underwent resection. We aim to identify which adjuvant therapy provides more survival benefits. METHODS: We identified patients who underwent oligodendroglioma resection in the Surveillance, Epidemiology and End Results (SEER) database. A multivariate Cox regression analysis was used to evaluate the factors affecting survival rates. We used a propensity matching analysis to minimize selection bias in each group. We performed subgroup analyses based on patients' clinical characteristics. RESULTS: This study identified 1826 patients who received adjuvant CT (n = 503) or adjuvant CRT (n = 1323). On multivariate analysis, elderly, white and other race, and temporal lobe and parietal lobe tumor site were independent risk factors for improved overall survival (OS). After 1:1 propensity match, we included 501 patients who received CT and 501 with CRT. Patients in the CT group showed improved overall survival rate compared with those who received CRT (median OS: 146 months vs. 111 months). Subgroup analysis showed that improved overall survival in CT group was more significant in patients who were younger or older, male or female, white race, frontal lobe and parietal lobe tumor site, smaller tumor size (≤4 cm), and with gross total resection (GTR) (P < 0.05). CONCLUSIONS: In patients with resected oligodendroglioma, adjuvant CT is associated with better survival compared to adjuvant CRT. The benefit was more significant in patients who were younger and older, male and female, white race, frontal lobe and parietal lobe tumor site, smaller tumor size (≤4 cm), and with GTR.

来源:World Neurosurg,查看原文。版权归原作者所有。

引用

  1. Liu K, Liao X, Chen Y, et al. Adjuvant Chemoradiation Therapy Versus Chemotherapy Alone for Resected Oligodendroglioma: A Surveillance, Epidemiology and End Results (SEER) Analysis. World Neurosurg. 2022. PMID: 36273731. doi:10.1016/j.wneu.2022.10.063

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。